top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
PRC961
Prostate cancer tissue array, 48 cases from hyperplastic and cancer tissues with progressive Gleason scores and TNM stages in duplicates.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$363
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
TNM Classification : Prostate carcinoma
T- Primary tumor
TX - Primary tumor cannot be assessed
TO - No evidence of primary tumor
T1 - Clinically inapparant tumor not palpable or visible by imaging
T1a - Tumor incidental histologic findings in 5% or less of tissue resected
T1 b - Tumor incidental histologic findings in more than 5% of tissue resected
T1c - Tumor identified by needle biopsy
T2 - Tumor confined within the prostate
T2a - Tumor involves one lobe
T2b - Tumor involves two lobes
T3 - Tumor extends through the prostate capsule
T3a - Extracapsular extension
T3b - Tumor invades seminal vesicle
T4 - Tumor is fixed or invades adjacent structures other than seminal vesicle: (bladder neck, external sphincter, rectum, levator muscle and/or pelvic wall
N - Regional lymph nodes
NX - Regional lymph nodes cannot be assessed
NO - No regional lymph node metastasis
N1 - Regional lymph node metastasis
M - Distant metastasis
MX - Distant metastasis cannot be assessed
MO - No distant metastasis
M1 - Distant metastasis
M1a - Non-regional lymph node(s)
M1b-Bone(s)
M1c-Other site(s)
Human
48
96
1.5mm
4um
8
12
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in evolution and progression of prostate cancers.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | M | 67 | Prostate | Hyperplasia | |||
A02 | M | 66 | Prostate | Hyperplasia | |||
A03 | M | 71 | Prostate | Hyperplasia | |||
A04 | M | 68 | Prostate | Hyperplasia | |||
A05 | M | 67 | Prostate | Hyperplasia | |||
A06 | M | 58 | Prostate | Hyperplasia | |||
A07 | M | 78 | Prostate | Hyperplasia | |||
A08 | M | 60 | Prostate | Hyperplasia | |||
A09 | M | 67 | Prostate | Hyperplasia | |||
A10 | M | 69 | Prostate | Hyperplasia | |||
A11 | M | 79 | Prostate | Hyperplasia | |||
A12 | M | 70 | Prostate | Hyperplasia | |||
B01 | M | 67 | Prostate | Hyperplasia | |||
B02 | M | 66 | Prostate | Hyperplasia | |||
B03 | M | 71 | Prostate | Hyperplasia | |||
B04 | M | 68 | Prostate | Hyperplasia | |||
B05 | M | 67 | Prostate | Hyperplasia | |||
B06 | M | 58 | Prostate | Hyperplasia | |||
B07 | M | 78 | Prostate | Hyperplasia | |||
B08 | M | 60 | Prostate | Hyperplasia | |||
B09 | M | 67 | Prostate | Hyperplasia | |||
B10 | M | 69 | Prostate | Hyperplasia | |||
B11 | M | 68 | Prostate | Hyperplasia | |||
B12 | M | 70 | Prostate | Hyperplasia | |||
C01 | M | 74 | Prostate | Adenocarcinoma | T2N0M0 | ||
C02 | M | 59 | Prostate | Adenocarcinoma | I | T2N0M0 | |
C03 | M | 69 | Prostate | Adenocarcinoma | T1N0M0 | ||
C04 | M | 77 | Prostate | Adenocarcinoma | T2N0M0 | ||
C05 | M | 60 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C06 | M | 76 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C07 | M | 79 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C08 | M | 73 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C09 | M | 73 | Prostate | Adenocarcinoma | II | T1N0M0 | |
C10 | M | 88 | Prostate | Adenocarcinoma | II | T2N0M0 | |
C11 | M | 69 | Prostate | Adenocarcinoma | III | T2N0M0 | |
C12 | M | 63 | Prostate | Adenocarcinoma | III | T3N0M0 | |
D01 | M | 74 | Prostate | Adenocarcinoma | T2N0M0 | ||
D02 | M | 59 | Prostate | Adenocarcinoma | I | T2N0M0 | |
D03 | M | 69 | Prostate | Adenocarcinoma | T1N0M0 | ||
D04 | M | 77 | Prostate | Adenocarcinoma | T2N0M0 | ||
D05 | M | 60 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D06 | M | 76 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D07 | M | 79 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D08 | M | 73 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D09 | M | 73 | Prostate | Adenocarcinoma | II | T1N0M0 | |
D10 | M | 88 | Prostate | Adenocarcinoma | II | T2N0M0 | |
D11 | M | 69 | Prostate | Adenocarcinoma | III | T2N0M0 | |
D12 | M | 63 | Prostate | Adenocarcinoma | III | T3N0M0 | |
E01 | M | 67 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
E02 | M | 70 | Prostate | Adenocarcinoma | T2N0M0 | ||
E03 | M | 70 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E04 | M | 77 | Prostate | Adenocarcinoma | III | T2N0M0 | |
E05 | M | 75 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E06 | M | 51 | Prostate | Adenocarcinoma | T3N1M0 | ||
E07 | M | 54 | Prostate | Adenocarcinoma | II | T1N0M0 | |
E08 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E09 | M | 78 | Prostate | Adenocarcinoma | T2N0M0 | ||
E10 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
E11 | M | 77 | Prostate | Adenocarcinoma | II~III | T1N0M0 | |
E12 | M | 73 | Prostate | Adenocarcinoma | T2N0M0 | ||
F01 | M | 67 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
F02 | M | 70 | Prostate | Adenocarcinoma | T2N0M0 | ||
F03 | M | 70 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F04 | M | 77 | Prostate | Adenocarcinoma | III | T2N0M0 | |
F05 | M | 75 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F06 | M | 51 | Prostate | Adenocarcinoma | T3N1M0 | ||
F07 | M | 54 | Prostate | Adenocarcinoma | II | T1N0M0 | |
F08 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F09 | M | 78 | Prostate | Adenocarcinoma | T2N0M0 | ||
F10 | M | 77 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F11 | M | 77 | Prostate | Adenocarcinoma | II~III | T1N0M0 | |
F12 | M | 73 | Prostate | Adenocarcinoma | T2N0M0 | ||
G01 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G02 | M | 70 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G03 | M | 79 | Prostate | Adenocarcinoma | T2N0M0 | ||
G04 | M | 55 | Prostate | Adenocarcinoma | II | T2N0M0 | |
G05 | M | 84 | Prostate | Adenocarcinoma | III | T1N0M0 | |
G06 | M | 73 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
G07 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G08 | M | 77 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
G09 | M | 78 | Prostate | Adenocarcinoma | T2N0M0 | ||
G10 | M | 68 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G11 | M | 78 | Prostate | Adenocarcinoma | III | T2N0M0 | |
G12 | M | 74 | Prostate | Adenocarcinoma | III | T3N0M0 | |
H01 | M | 75 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H02 | M | 70 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H03 | M | 79 | Prostate | Adenocarcinoma | T2N0M0 | ||
H04 | M | 55 | Prostate | Adenocarcinoma | II | T2N0M0 | |
H05 | M | 84 | Prostate | Adenocarcinoma | III | T1N0M0 | |
H06 | M | 73 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
H07 | M | 73 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H08 | M | 77 | Prostate | Adenocarcinoma | II~III | T2N0M0 | |
H09 | M | 78 | Prostate | Adenocarcinoma | T2N0M0 | ||
H10 | M | 68 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H11 | M | 78 | Prostate | Adenocarcinoma | III | T2N0M0 | |
H12 | M | 74 | Prostate | Adenocarcinoma | III | T3N0M0 | |
null |
bottom of page